Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells

Human Vaccines

Volumn 4, Issue 5, 2008, Pages 370-374

  Guttormsen, Hilde Kari ^a   Liu, Yongdong ^a   Paoletti, Lawrence C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Glycoconjugate vaccines; Group B Streptococcus; HL 60 cells; Opsonophagocytosis assay

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; STREPTOCOCCUS VACCINE;

ANTIBODY DETECTION; ARTICLE; CELL ASSAY; CELL DEATH; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; EFFECTOR CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; OPSONIZATION; OPSONOPHAGOCYTOSIS ASSAY; PHAGOCYTOSIS; STANDARDIZATION; STREPTOCOCCUS AGALACTIAE;

EID: 54949089999     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.5.5988     Document Type: Article

References (22)

1. Paoletti LC, McInnes P, eds. Vaccines: From Concept to Clinic. A guide to the development and clinical testing of vaccines for human use. Boca Raton, FL: CRC Press 1999.
2. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 2002; 67:37988-98.
3. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12.
4. Schrag SJ, Zywicki S, Parley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15-20.
5. Paoletti LC. Academic pursuits of vaccines against group B Streptococcus. In: Ellis RW, Brodeur BR, eds. New Bacterial Vaccines. Georgetown, TX: Eureka.com and Kluwer Academic/Plenum 2003; 174-91.
6. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-72.
7. Baltimore RS, Baker CJ, Kasper DL. Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun 1981; 32:56-61.
8. Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. Immune response to type III group B streptococcal polysaccharide- tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98:2308-14.
9. Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen HK. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 2002; 185:1277-84.
10. Romero Steiner S, Frasch C, Concepcion N, Goldblatt D, Kayhty H, Vakevainen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, Plikaytis BD, Carlone GM. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diag Lab Immunol 2003; 10:1019-24.
11. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diag Lab Immunol 1997; 4:415-22.
12. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006; 13:1004-9.
13. Fusco PC, Perry JW, Liang SM, Blake MS, Michon F, Tai JY. Bactericidal activity elicited by the beta C protein of group B streptococci contrasted with capsular polysaccharides. Adv Exp Med Biol 1997; 418:841-5.
14. Michon F, Fusco PC, D'Ambra AJ, Laude Sharp M, Long Rowe K, Blake MS, Tai JY. Combination conjugate vaccines against multiple serotypes of group B streptococci. Adv Exp Med Biol 1997; 418:847-50.
15. Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B Streptococcus beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 2007; 75:3455-61.
16. Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diag Lab Immunol 2005; 12:19-27.
17. Romero Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165-9.
18. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 1990; 86:1428-33.
19. Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun 2002; 70:1724-38.
20. Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996; 173:142-50.
21. Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179:142-50.
22. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1993; 61:4760-6.